Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge

Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge

Source: 
Fierce Biotech
snippet: 

Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition of Kite Pharma.